trimetrexate has been researched along with AIDS-Related Opportunistic Infections in 18 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of clindamycin plus primaquine appears to be the most effective alternative treatment for patients with P carinii pneumonia who are unresponsive to conventional antipneumocystis agents." | 4.81 | A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. ( Maloba, B; Nagar, S; Popara, M; Smego, RA, 2001) |
| " Serial blood samples were obtained over 24 hours after dosing and analyzed for trimetrexate, dapsone, and monoacetyldapsone, and pharmacokinetic parameters were determined." | 2.69 | Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. ( Chatterjee, DJ; Dubé, MP; Koda, RT; Li, WY; Sattler, FR; Stansell, JD, 1999) |
| "Trimetrexate is a powerful inhibitor of the dihydrofolate reductase of Pneumocystis carinii." | 2.67 | Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/0 ( Akil, B; Baughman, R; Boylen, CT; Davis, R; Frame, P; Hughlett, C; Nichols, L; Sattler, FR; Shelton, B; Weiss, W, 1994) |
| "Trimetrexate is a folinic acid analogue structurally related to methotrexate, whose primary mechanism of action is believed to be inhibition of dihydrofolate reductase." | 2.39 | Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. ( Fulton, B; McTavish, D; Wagstaff, AJ, 1995) |
| "Trimetrexate was tolerated in 100% of cases with no treatment termination secondary to adverse drug reactions." | 1.35 | Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia. ( Churchill, DR; Fisher, MJ; Gilleece, YC; Short, CE, 2009) |
| "The P & T Committee at Trinity Lutheran Hospital, a 320-bed, community/teaching hospital in Kansas City, MO, has developed dosing and monitoring guidelines for foscarnet sodium (Foscavir) and trimetrexate glucuronate (Neutrexin)--two drugs used to treat patients with opportunistic infections associated with the human immunodeficiency virus (HIV)." | 1.29 | Dosing guidelines for foscarnet and trimetrexate. ( Chase, K; Henry, RB; O'Connor, MC; Wooten, JM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (83.33) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A | 3 |
| Devraj, R | 1 |
| Queener, SF | 3 |
| Vasudevan, A | 2 |
| Short, CE | 1 |
| Gilleece, YC | 1 |
| Fisher, MJ | 1 |
| Churchill, DR | 1 |
| Borde, JP | 1 |
| Offensperger, WB | 1 |
| de With, K | 1 |
| Fulton, B | 1 |
| Wagstaff, AJ | 1 |
| McTavish, D | 1 |
| Pastor, C | 1 |
| Lumbreras, C | 1 |
| Lizasoain, M | 1 |
| Sattler, FR | 2 |
| Frame, P | 1 |
| Davis, R | 1 |
| Nichols, L | 1 |
| Shelton, B | 1 |
| Akil, B | 1 |
| Baughman, R | 1 |
| Hughlett, C | 1 |
| Weiss, W | 1 |
| Boylen, CT | 1 |
| Freij, BJ | 1 |
| Wientzen, RL | 1 |
| Hayek, G | 1 |
| Whitfield, LR | 1 |
| Voelker, R | 1 |
| Korraa, H | 1 |
| Saadeh, C | 1 |
| Deresinski, SC | 1 |
| Koda, RT | 1 |
| Dubé, MP | 1 |
| Li, WY | 1 |
| Chatterjee, DJ | 1 |
| Stansell, JD | 1 |
| Wooten, JM | 1 |
| Chase, K | 1 |
| O'Connor, MC | 1 |
| Henry, RB | 1 |
| Harris, PJ | 1 |
| Blanchet, KD | 1 |
| Smego, RA | 1 |
| Nagar, S | 1 |
| Maloba, B | 1 |
| Popara, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS[NCT00001014] | Phase 3 | 302 participants | Interventional | Completed | |||
| A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS[NCT00001013] | Phase 3 | 364 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for trimetrexate and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
[Diagnosis and treatment of pneumocystis jirovecii pneumonia].
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Atovaquone; Broncho | 2011 |
Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Animals; Clinical Trials as Topic; Humans; Pneumonia, Pneumoc | 1995 |
[Current alternatives in the treatment of Pneumocystis carinii pneumonia in patients with AIDS].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Eflornit | 1994 |
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Ag | 1996 |
Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifunga | 1997 |
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Clindamycin | 2001 |
2 trials available for trimetrexate and AIDS-Related Opportunistic Infections
10 other studies available for trimetrexate and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Liver; Pyrimidines; Rats; Te | 1997 |
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Topics: AIDS-Related Opportunistic Infections; Animals; Binding Sites; Folic Acid Antagonists; Humans; Indic | 1997 |
Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Evaluation; Drug Therapy, Comb | 2009 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Pharmacokinetics of trimetrexate glucuronate in infants with AIDS and Pneumocystis carinii pneumonia.
Topics: AIDS-Related Opportunistic Infections; Drug Combinations; Female; Glucuronates; Humans; Infant; Male | 1993 |
More choices in treating AIDS-related pneumonia.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Approval; Drug Combinations; Glucuron | 1994 |
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Liver; Mice; Pneumoc | 1997 |
Dosing guidelines for foscarnet and trimetrexate.
Topics: AIDS-Related Opportunistic Infections; Clinical Protocols; Dose-Response Relationship, Drug; Foscarn | 1995 |
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Drug Combinations; Glucuronates | 1996 |
Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP).
Topics: AIDS-Related Opportunistic Infections; Algorithms; Anti-Infective Agents; Antifungal Agents; Dapsone | 1996 |